ArticleCureus2026
Socioeconomic Vulnerability and Alcohol Relapse After Liver Transplantation for Alcohol-Associated Liver Disease: A Retrospective Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Alcohol relapse after liver transplantation for alcohol-associated liver disease is clinically consequential, yet the predictive value of commonly used pre-transplant psychosocial tools remains inconsistent. We evaluated pre-transplant psychosocial, socioeconomic, biomarker, and clinical variables associated with post-transplant alcohol relapse. Methods We performed a single-center retrospective cohort study of adults transplanted for alcohol-associated liver disease from January 2020 through February 2026. Relapse was defined as any post-transplant alcohol use by self-report or positive phosphatidylethanol (PEth) (or blood alcohol concentration (BAC) testing. Candidate predictors included employment status, age, Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder-7 (GAD-7), Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT), CAGE score, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) severity, support plan quality, pre-transplant phosphatidylethanol, sobriety duration, and substance use history. PHQ-9, GAD-7, and SIPAT values were harmonized into standard severity categories before analysis. Univariable testing used chi-square, Fisher's exact, and Mann-Whitney U tests. Logistic regression used complete cases for each predictor. Results Of 340 reviewed patients, 38 were excluded because their relapse status was indeterminate, leaving 302 patients. Twenty patients met relapse criteria; 13 of 20 events occurred beyond 12 months post-transplant. Employment status was associated with relapse: 14 of 120 unemployed patients relapsed, compared with 3 of 78 employed patients and 1 of 49 retired patients. Unemployment was associated with increased relapse odds (odds ratio (OR) 4.061, 95% confidence interval (CI) 1.297-12.714, p = 0.016). Relapsed patients were younger than non-relapsed patients, and age was inversely associated with relapse odds (OR 0.950 per year, 95% CI 0.909-0.993, p = 0.023). PHQ-9 showed a borderline, non-linear pattern, while SIPAT, sobriety duration, pre-transplant phosphatidylethanol, CAGE, DSM-5 severity, and support plan quality were not associated with relapse. Conclusions Unemployment and younger age were associated with post-transplant alcohol relapse, whereas several conventional pre-transplant tools did not stratify relapse risk. Employment status should not be used as an exclusion criterion but may identify socioeconomic vulnerability warranting enhanced post-transplant monitoring and support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.